Cardium Therapeutics has completed the second tranche of its previously announced registered direct offering consisting of an additional 1,656 shares of Series A convertible preferred stock for gross proceeds of approximately $1.7 million, bringing the total gross proceeds of the … Continue reading →

Cardium Therapeutics, an asset-based health sciences and regenerative medicine company, announced a 1-for-20 reverse split of the company’s issued and outstanding common stock, effective today at market open, reducing the number of issued and outstanding common shares to approximately 6.5 … Continue reading →

Cardium Therapeutics focuses on the fields of health sciences and regenerative medicine to carry out its business model of acquiring and developing new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs. Prospective … Continue reading →

Cardium Therapeutics, a San Diego based health sciences and regenerative medicine company, is remarkably well balanced for ongoing growth in the health and therapeutic marketplace. The company has products that cover the range from well-established revenue generators, to relatively recently … Continue reading →

Ask any physician or health care professional what America’s biggest single health problem is and you will likely get an answer that points to cardiovascular disease and the lifestyle issues that promote it, such as obesity. Heart disease has long … Continue reading →

Cardium Therapeutics has established a diversified portfolio of medical products with large market potential. Armed with a capital-efficient, asset-based business strategy, the company is positioned to continue to build its portfolio with balanced risk/return opportunities in a variety of markets … Continue reading →

It’s not something you’d expect to find in a regenerative medicine company’s portfolio, but Cardium Therapeutics’ To Go Brands healthy nutraceutical supplement business is complementary to the company’s overarching mission of meeting unmet medical needs as part of an individual’s … Continue reading →

When we contemplate the effects that digital electronics has had on health, we are likely to think of the truly amazing progress made in things like medical diagnostics or medical information processing and communication. What is becoming increasingly clear, however, … Continue reading →

Today before the opening bell, Cardium Therapeutics announced that Institutional Shareholder Services, Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”), the nation’s leading independent proxy advisory firms, each recommend that Cardium’s stockholders vote “FOR” all proposals in the … Continue reading →